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Abstract 
Alzheimer's disease (AD) is a heterogeneous neurodegenerative disorder occurring in the 
elderly, affecting approximately 5% of individuals over 65 and 20% of those over 80. As 
yet, there is no effective treatment available. One of the neuropathological hallmarks of A D 
is the accumulation of intracellular neurofibrillary tangles which are comprised of 
aggregates of paired helical filaments (PHF). The principal component of PHF has been 
shown to be tau, a microtubule-associated protein involved in stabilizing the cytoskeleton 
and in determining neuronal shape. Abnormal phosphorylation of tau by various kinases 
including glycogen synthase kinase-3p (GSK-Sp) and cyclin-dependent kinase is the 
principal mechanism for its aggregation into PHF. Therefore, less PHF will be formed if 
phosphorylation of tau is reduced, and thus less neurons will be degenerated. 
Danshen (丹參）is traditionally used for the treatment of menstrual disorder, menostasis， 
Menorrhagia, insomnia, blood circulation disease and angina pectoris. The reference, 
Chang Jian Nao Bing Liang Fang 1500 Shou (常見腦病良方 1500 首）meaning "A 
collection of 1500 commonly used formula", contains 500 Chinese medicine formulas for 
treating brain disease. Danshen has about 35% occurrence in these formulas which 
indicating it may have positive effect on brain diseases. 
In the first part of m y study, I have investigated the effect of Danshen and its active 
components protocatechualdehyde (PCAH) and salvianolic acid B (SAB) on GSK-3P 
induced hyperphosphorylation of tau. Different epitopes of hyperphosphorylated tau 
proteins were analyzed by using different antibodies (AT-270, AT-180，AT-8, PHF-1, HT-7 
and Tau), for the effect of Danshen. P C A H and SAB were found to reduce GSK-3(3 
induced tau phosphorylation. In the second part of the study, the effect of P C A H and SAB 
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on tau phosphorylation by Cdk-5/p35 was investigated. Only PC A H can reduce tau 
phosphorylation induced by Cdk-5. 
In recent years, oxidative imbalance is emerging as an important issue in AD. Antioxidants 
that prevent the detrimental consequences of reactive oxygen species are consequently 
considered to be a promising approach to neuroprotection. Antioxidants constitute many 
clinical and experimental drugs that are currently considered for A D prevention and 
therapy. By using red-blood-cell hemolysis assay, antioxidant effect of Danshen, P C A H 
and SAB were investigated and the result indicated that SAB (IC50 = 17.3 |jM) was more 
effective than P C A H (IC50 二 23.3 ^ iM) and significantly more effective than ascorbic acid 
















抗體（AT-270，AT-180’ AT-8，PHF-1 ‘ HT-7 and Tau)，分析丹參對 tau 蛋 
白不同位置隣酸化的情況。發現PCAH和SAB能減少GSK-3P誘發的tau蛋 






的抗氧化功能，顯示SAB (IC50 = 17.3 ^ iM)的抗氧化能力明顯較PCAH (IC50 = 
23.3 i^M)和抗壞血酸（IC50 = 139.3 |aM)爲佳。 
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Chapter 1 Introduction 
1.1 Alzheimer's Disease 
Alzheimer's disease (AD), the most common cause of dementia, is a devastating 
illness characterized by cognitive deterioration as well as behavioral, affective, and 
psychotic disturbances (Dekosky, 1996). It is estimated that there are approximately 
15 million people suffering from A D worldwide. The initiating molecular event of 
A D is not known, and its pathophysiology is highly complex. The classical 
pathological hallmarks of A D are the accumulation of senile neuritic plaques and 
neurofibrillary tangles in the brain. Extracellular amyloid plaque contains beta-
amyloid and intracellular neurofibrillary tangle contains polymerized and 
hyperphosphorylated tau protein. Several independent parameters have been 
suggested as the primary factor that is responsible for this pathogenesis, including 
apolipoprotein E genotype, hyperphosphorylation of cytoskeletal proteins, or 
metabolism of beta-amyloid peptide. However, many scientists suggested that it might 
involve overlapping pathways of neuronal damage. 
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1.1.1 Clinical features 
A D was named after the physician Alois Alzheimer in 1907 who reported the case of 
an elderly female patient who had severe cognitive impairments and a characteristic 
pathology within the brain. Affected individuals show abnormalities of memory, 
problem solving, language, calculation, visuospatial perceptions, judgment and 
behavior (McKhann et al” 1984). Some of them also show psychotic symptoms like 
hallucinations and delusions. Their daily living activities become increasingly 
impaired and usually die of intercurrent medical illness. 
1.2 Histopathological studies of AD 
1.2.1 Neuritic plaques 
Neuritic plaques are composed of extracellular spherical deposits of beta-amyloid 
protein (Ap) (Glenner and Wong, 1984), which are intimately associated with 
dystrophic axons and dendrites as well as activated microglia and reactive astrocytes 
(Selkoe, 1996). They are abundant in the amygdala, hippocampus and neocortex in 
the case of A D (McKhann et aL, 1984; Morris et al., 1996). Ap is composed of 34 to 
43 amino acids and is produced under normal metabolic conditions from amyloid 
precursor protein (APP). The deposition of Ap appears to be the earliest 
morphological change in the formation of neuritic plaques (Mann and Esiri，1989). 
Variants of Ap, which differ only at their C-terminus, are found in extracellular and 
cerebrovascular plaques. This hydrophobic C-terminal sequence is a critical 
determinant of solubility, affecting the rate of amyloid formation. Soluble A|3 is 
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composed primarily of a 40-amino acid protein (Ap 40) with only small amounts of 
the 42 or 43 amino acid isoforms (Ap 42/43). The Ap 42/43 variant forms insoluble 
fibrils much faster than Ap 40 in vitro (Jarrett et al., 1993). Furthermore, coincubation 
of small amounts of Ap 42/43 with Ap 40 results in immediate aggregation, 
indicating that amyloid plaques may be seeded by trace amounts of this component. 
The term "diffuse plaques" refers to deposits of Ap without the surrounding neuritic 
degeneration (Dekosky et al., 1996). It is believed that diffuse plaques contain the 
soluble, nonfibrillary form of Ap and may represent an early stage of senile plaques 
(Bugiani et al” 1995). 
Besides, the density of senile plaques does not increase with age, the mechanism for 
switching the plaque-free to plaque-bearing status is unknown. Ap was released from 
APP by the proteolytic actions of a, P and y secretase. Significiantly, Ap42 appears to 
be toxic to nerve cells (Yankner, 1996)，but the mechanisms of Ap 
fibrillogenesis/toxicity are not well understood. 
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1.2.2 Neurofibrillary tangles (NFT) 
Neurofibrillary tangles (NFTs) are a distinguishing neuropathological feature found in 
postmortem brains of Alzheimer 's disease (AD) and tauopathy patients. The density 
of these lesions correlates with severity of A D and their distribution follows a 
characteristic pattern of expansion as the disease progresses. NFTs are inclusion 
bodies that consist of filamentous aggregates of paired helical filaments (PHF) within 
the neuronal cytoplasm. Aggregated phosphorylated Tau proteins are the basic 
components of PHF. Their presence signifies the failure of the neuron to properly 
maintain its skeleton, which is required to support the extraordinarily complex 
branching shape of its numerous processes. A small number of neurofibrillary tangles 
are a universal consequence of aging. However, it is an increased number and the 
architectonic distribution of the tangles that promote the cardinal pathology and 
define the stages of the disease (Braak and Braak，1991). The development of tangles 
is a major and possibly the main mechanism of neuronal death in A D (Gomez et al” 
1997). Tangles frequently occur in the hippocampus in the brain that is involved in 
processing experiences prior to storage as permanent memories. This correlates with 
the clinical deficits observed in the early stages of A D in learning and in the creation 
of new memories, as well as with the relative preservation of established memories. 
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1.2.3 Tau 
Tau proteins belong to the family of microtubule associated protein which is normally 
enriched in axons. They were originally identified as the low-molecular weight 
component of a protein fraction co-purified with brain microtubules during repeated 
assembly/disassembly cycles (Weingarten et al., 1975; Cleveland et aL, 1977). They 
regulate the dynamics of microtubule network, especially involved in the axonal 
transport. In adult human brain, a single tau gene transcript is alternatively spliced and 
six tau protein isoforais are translated from m R N A s (Goedert et al., 1992). The tau 
isoforms vary in length between 352 and 441 amino acids. The isoforms differ from 
each other by possession of one or two amino terminal inserts of unknown function 
and three or four domain sites for interaction between tau and tubulin (Lovestone et 
al, 1997). All six isoforms have been reported to be present in a hyperphosphorylated 
state in PHF (Fig 1.1) (Singh et al,，1996). 
In AD, tau proteins polymerize into PHF, are ubiquitinated and partially proteolytzed 
(Morishima and Ihara, 1994), glycated (Ledesma et al., 1994) and also oxidized, but 
the most striking feature is their very high level of phosphorylation (Grundke-Iqbal et 
al,, 1986; Delacourte et al., 1990; Brion et al., 1991). They can be phosphorylated by 
several kinases including GSK-3 p and Cdk5. This phosphorylation causes a reduction 
in mobility on electrophoresis, which can be reversed by dephosphorylation either 
chemically or enzymatically with phosphatase (McKhann et al., 1984). 
Phosphorylation of Tau protein is considered to be the cause of PHF formation and 
might be a key event in degenerating neurons, suggesting a dysregulation of the 
balance of kinase and phosphatase activities. Prevention of tau aggregation is a 
possible therapeutic target for A D treatment. 
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Fig. 1.1 Schematic representation of the structure of the six human tau isoforms. 
The numbers of amino acids are indicated on the right of each tau isoform. It varies 
between 352 and 441 amino acids. Adult human brain tau protein isoforms either 
differ by the presence or absence of three amino acids inserts translated from exons 2， 
3 and 10，respectively. The composition of tau isoforms with those threee translated 
exons is represented on right by + or - signs adjacent to exon number. (Goedert, 
1993). 
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1.3 Kinases and Alzheimer's disease 
Tau is a substrate of numerous protein kinases and is regulated by differential 
phosphorylation of its serine and threonine residues. Phosphorylation of tau within the 
microtubule-interacting regions reduces its ability to bind to microtubules and 
consequently promotes their disassembly (Mandelkow et aL, 1995). Tau and other 
cytoskeletal regulatory proteins may play an important role in facilitating the 
cytoskeletal reorganization that occurs during apoptotic cell death (Levee et al., 1996). 
Different protein kinases are involved in tau phosphorylation. These include glycogen 
synthase kinase 3 (GSK-3)，MARK kinase, M A P kinase，the cyclin-dependent kinase 
5 (Cdk-5) system and others. Only GSK-3 (3 and Cdk-5 have been copurified with 
microtubules (Ishiguro et al., 1992; Hosoi et al., 1995) and only these two kinases 
can phosphorylate tau in a cellular environment (Wagner et al” 1996; Michel et al., 
1998). 
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1.4 Free radical damage 
A free radical is an atom or molecule with an unpaired electron in its outer orbit, a 
state that makes it highly unstable and reactive. Free radicals are formed during 
normal metabolism, and free radical injury occurs with living cells when the 
generation of reactive species exceeds intrinsic antioxidant ability. This situation is 
also referred to as oxidative or oxidant stress (Pratico and Delanty，2000). Oxidative 
stress is associated with formation of carbonyls from lipids, carbohydrates and 
proteins (reviewed in Stadtman, 1992). 
Oxidative stress is believed to be a critical factor in neurodegenerative diseases such 
as Alzheimer's disease. Formation of free carbonyls (Smith et al, 1991) and 
thiobarbituric acid-reactive products (Subbarao et al, 1990) an index of oxidative 
damage, is significantly increased in A D brain tissue compared with age-matched 
controls. Plaques and tangles display immunoreactivity for antioxidant enzymes 
(Pappolla et al., 1992). There are multiple mechanisms by which cellular alterations 
may be induced by oxidative stress, including production of reactive oxygen species 
(ROS) in the cell membrane (lipid peroxidation). 
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1.5 Available treatment for AD 
Acetylcholinesterase (Ache) inhibitor drugs are the only group of drugs currently 
licensed for A D treatment (McGleenon et al., 1999). It blocks the hydrolysis of 
acetylcholine, enabling acetylcholine to accumulate in the synaptic cleft. This allows 
for a prolonged action at cholinergic receptors, which may compensate for the loss of 
cholinergic neurons in A D patients (Jann, 1998). 
There are many Ache inhibitor drugs including tacrine, donepezil, rivastigmine and 
galantamine. Tacrine, an aminoacridine, has several actions such as monoamine 
oxidase inhibition, potassium channel blockade and interaction with subtypes of 
muscarinic and nicotinic receptors. However, the most prominent action is as a 
centrally active reversible cholinesterase inhibitor (Cutler et al., 1990). Besides, 
donepezil which is a specifically designed piperidine derivative containing reversible 
acetylcholinesterase inhibitor activity. It has a much higher specificity for 
acetylcholinesterase inhibition compared with tacrine (Sugimoto et al” 1992) and its 
CNS selectivity is highlighted by the lack of activity in peripheral tissue such as 
cardiac tissue or gut smooth muscle (Mohs et al., 2001). Rivastigmine is a brain 
selective carbamate AChe inhibitor. It is known as a 'pseudo-irreversible' inhibitor 
because it mimics acetylcholine by binding with the enzyme Ache forming a 
carbamylated complex (Kumar et al” 2000). Galantamine can reversibly and 
competitively inhibit AChe and enhance the response of nicotinic receptors to 
acetylcholine. This enhancement of nicotinic neurotransmittion may be clinically 
relevant because of activation of presynaptic nicotinic receptors increases the release 
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of acetylcholine and other neurotransmitters, such as glutamate that are deficient in 
patients with A D (Lawrence and Sahakian, 1998; Francis et al., 1999). 
However, AChe inhibitor drugs are associated with several adverse events that are 
probably caused by peripheral acetylcholine inhibition. In addition to gastrointestinal 
effects and leg cramps, patients treated with AChe inhibitor drugs may experience 
mild bradycardia. The decline in heart rate is usually 5 beats/min; if the heart rate falls 
to 50 beats/min, electrocardiographic monitoring is needed. Discontinuation of the 
drug is advisable if the heart rate falls to 45 beats/min or below. 
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1.6 A Chinese medicinal material - Danshen {Salviae miltiorrhizae) 
Danshen (Radix Salviae miltiorhizae) is the dry root and rhizome of Salvia miltiorhiza 
B U N G E (Lamiaceae). It has a bitter taste and is nontoxic. It is listed in the Chinese 
Pharmacopoeia of year 2000 (Pharmacopoecia Committee of the Health Ministry of 
the People's Republic of China (ed.)) and used for treatment of menstrual disorder, 
menostasis, menorrhalgia, insomnia, blood circulation diseases and angina pectoris as 
well as against inflammation (Namba et al., 1993). 
1.6.1 Chemical constituents 
Compounds in Danshen may be divided into water-soluble and lipid-soluble. 
Lipophilic compounds are tanshinone I, tanshinone IIA, tanshinone IIB, 
cryptotanshinone, hydroxytanshinone IIA, methyltanshinoate, isotanshinone I， 
isotanshinone IIA, isocryptotanshinone I，miltirone, methylenetanshinquinone, 
dihydrotanshiiione I，1,2-dihydrotanshinquinone, dehydromiltirone, danshenxinkun A， 
B，C，tanshinone V, tanshinone VI. Water-soluble compounds identified are 
protocate-chualdehyde, caffeic acid, salvianolic acid A, B, C，rosmarinic acid, methyl 
rosmarinate, salviol，tanshinol A, B，C，ferruginol, tigogenin and lithospermic acid B. 
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1.6.1.1 Lipophilic Compounds of Danshen 
O O 
Tanshinone I C18H12O3 Cryptotanshinone C19H20O3 
o i H o 
Ri 
Danshenxinkun A C18H16O4 Tanshinone IIA C19H18O3 
R二 —c义闩3 Ri= CH3, R2=H 
—hrCH2〇H 
Danshenxinkun B C18H16O3 Tanshinone IIB C19H18O4 
_ _ /CH3 Ri= CH2OH, R2=H 
Danshenxinkun C C16H12O3 Methyltanshinonate C20H18O5 
R=CH3 RI=C〇〇CH3，R2=H 
Hydroxytanshinone IIA C19H18O4 
R i=CH3 , R2=〇H 
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。r^ 
Isotanshinone I C18H12O3 (Kakisawa et al., 1969) 
Isotanshinone II A C19H18O3 (Kakisawa et al., 1969) 
Z 、CH20H 
Isotanshinone II B C19H18O4 (Lee et al., 1987) 
Isocryptotanshinone C19H20O3 (Kakisawa et aL, 1969) 
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Miltirone I C18H16O2 (Quitsuka et al., 1983) 
Miltirone C19H22O2 (Luo et al, 1988; Chang，1990) 
。“rVi 
CH2 
Methylene-tanshinquinone C18H14O3 (Feng, 1980) 
yVi 




1,2-dihydrotanshinquinone CigH^Os (Feng, 1980) 
Dehydromiltirone C19H20O2 (Hayashi et al., 1970) 
HO CH2OH 
Tanshindiol A CigHigOs (Luo , 1985) 
o 
Nortanshinone C17H12O4 (Luo，1985) 
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Danshenxinkun D C20H21O4 
r < 
Dihydroisotanshinone I C18H14O3 (Kong，1984) 
。Ai 
3a-Hydroxytanshinone IIA C19H18O4 (Luo , 1985) 
OH 
Ferruginol C20H30O (Nateanishi et al, 1985) 
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1.6.1.2 Water-soluble Compounds 
R2O Rz 
\ = J H " C O O R , 
Ri R2 R3 R4 
Caffeic acid 
C9H8O4 H H H 
O H 
Rosmarinic C O O H ^ 
acid CisH,608 -c-CH,- —OH 
I S O 二 n CHs H H 
acid C10H10O4 
Salvianolic oh oh 
. C O O H 一 
acid A H H -c.c- -OH 一 -OH 
C 2 6 H 2 2 0 , O H H 一 H 2 一 
Salvianolic oh 
acidD H H —�COOH ？ooh _ 
"2 - c - C H f — O H 
C20H18O10 H 一 
900R2 




Lithospermic acid ？ o o h 二 
C27H22O12 1 - C H 2 - — - O H H 
O H O H 
Salvianolic acid B c o o h 二 c o o h 二 ^ 
C36H3oO,6 —白-CH2- — - O H C - C H ^ —OH 
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O 0 \ \ 、 O H 
i 丨 I \ 
H 1 COOH、k.oH 
n S 
H O 、 、 〇 
H O \ 
Salvianolic acid C C27H22O9 
C O O R 
H C = C H 〜• 
\ R 0 0 £ I C O O H _ _ / 〇 H 
H O \丨 H O 、〕 h \ _ J J 
O H O H 
Salvianolic acid E C27H21O12 
h o - Y o r 
O H 
R 
Salvianic acid A H 
C9H10O5 




HO R1OOC H ^ H 
O H H O Y y V j ] \ = / 
OH 
CHO — — O H 
OH 
Rl, ？OOH _ 
R2 : —fi—CH2- 一 -OH 
Protocatechualdehyde C7H6O3 Salvianolic acid B C36H30O16 
Fig. 1.2 Chemical structures of active components of Danshen (Protocatechualdehyde 
(PCAH) and Salvianolic acid B (SAB)). PCAH and SAB will be used for further 
studied. 
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1.6.2 Pharmacological usage 
1.6.2.1 Action on Coronary system 
Intravenous infusion of Danshen injection to anesthetized dogs or cats at the dose of 
3-4 g/kg significantly increased coronary flow and lowered coronary resistance, but 
increased myocardial oxygen consumption (Coronary Disease Research Group, 1974; 
Zhongshan Teaching Hospital, 1976). The injection of Danshen increases the flow 
rate in the aorta and the circumflex branch of the left coronary artery (Yang et al, 
1979). 
Rabbits or rats with acute myocardial ischemia induced by pituitrin could be 
improved or counteracted by treatment with Danshen (Chemistry of Nature Drugs 
Section, 1980). It can also be used to reduce the injuries due to acute myocardial 
ischemia and accelerate the recovery of the ischemic area (Zhongshan Teaching 
Hospital, 1976). Electron microscopy of the heart tissues showed more active 
phagocytosis and less necrotic myocardial residual flakes in the Danshen injection 
group, which also had marked fibroblast differentiation and interstitial hyperplasia as 
well as less capillary damage (Zhongshan Teaching Hospital, 1976). Danshen 
injection can also promote the regeneration of myocardial cells in the infracted area 
(Zhongshan Teaching Hospital, 1976)，and reduce the damage to the intercalated disk 
of the ischemic myocardium (Fan et al., 1979). In isolated heart of guinea pig or 
rabbit, Danshen can be used to decrease the heart rate and transiently decrease the 
cardiac contractility and then increase it (Sang et al” 1979). 
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1.6.2.2 Bacteriostatic action 
Danshen showed inhibitory effect against Staphylococus aureus, Escherichia coli, 
Proteus vulgaris, Shigella flexneri and Salmonella typhi in in vitro bacteriostatic 
studies (Zhejiang People's Academy of Health, 1972). Besides, in vitro and semi in 
vivo studies showed that it can also inhibit Leptospira (Zhejiang People's Academy of 
Health, 1972). Total tanshinones, crytotanshinone, tanshinone IIB, hydroxytanshinone 
IIA, dihydrotanshinone and methyl tanshinone all showed strong inhibition against 
Staphylococus aureus in in vitro studies. 
1.6.2.3 Actions on the immune system 
Traditional Chinese medicine, "huo xie hua yu", a water-soluble component extracted 
from Radix Salvia miltiorrhiza Bge. has been used for the treatment of hyperviscosity 
syndrome. Results showed that this extract promotes macrophage proliferation in 
vitro and enhances macrophage synthesis of C4 component of complements but not 
other complement. Twenty patients with with hyperviscosity syndrome treated with 
an aqueous extract of Danshen, had serum levels of C4 rose significantly over the 
course of treatment. The rise in C4 levels closely correlated with the disappearance of 
the patients' clinical symptoms. 
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1.6.3 Biological activity on brain 
Danshen exhibits neuroprotective effect on anoxic damage in hippocampal neurons in 
ischemia and ischemia-reperfusion rats. Its effect on anoxic damage in cultured 
hippocampal neurons of neuronatal rat was investigated by using morphological 
changes and heat shock protein 70 kDa (HSP 70) expression as indicators. Danshen 
given 0.5 hour before 2-hours anoxia followed by 48 hours reoxygenation could 
significantly increase survival rate of hippocampal neurons and number of HSP70 
positive cell (Liu et al., 1998). 
Previous studies demonstrated that Danshen could reduce ultrastructural abnormalities 
in the cortical, hippocampal and caudate neucleus areas brought by forebrain ischemia 
(Wu et al., 1992). Besides, in rats pretreated with Danshen, the number of apoptotic 
cells reduced significantly and the neuronal damage was much milder as compared 
with those of saline-treated rats. Danshen showed protective effect on apoptosis of 
neurons during focal cerebral ischemia and reperfusion injury and afford significant 
cerebroprotection in the model of focal cerebral ischemia and reperfusion (Wu 'et al, 
1997). 
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1.7 Objectives and scope of the project 
The pathology of Alzheimer's disease is very complex and many scientists believe 
that it might involve overlapping pathways of neuronal damage. Neurofibrillary 
tangles (NFTs) and senile plaques constitute two prominent neuropathological 
characteristics of A D (Kosik et al., 1991). Hyperphosphorylated tau is an integral part 
of the NFTs that form within neuronal cell bodies and fails to promote microtubule 
assembly. Dysregulation of the brain specific tau protein kinases (GSK-3 p and Cdk-5) 
were reported to play important role in the pathogenesis of A D (Patrick et al., 1999). 
From the reference, Chang Jian Bing Liang Fang 1500 Shou (常見腦病良方 1500 首)， 
there are 500 Chinese medicine formulas which have been applied for the treatment 
of brain disease. Danshen (丹參）has about 35% occurrence in these formulae 
indicating that it may be effective on brain diseases. 
The aims of m y study were therefore (1) Investigation of the effect of Danshen and its 
active components (PCAH and SAB) on GSK-3(3 induced hyperphosphorylation of 
tau. By using different antidodies (AT-270, AT-180, AT-8，PHF-1, HT-7 and Tau), 
hyperphosphorylated tau proteins were analyzed in different sites. (2) Investigation on 
Cdk-5 induced tau phosphorylation by using cell model transfected with p35 and 
tauONSR. Finally, (3) antioxidant effects of Danshen, P C A H and SAB were 
investigated by using red-blood-cell hemolysis model. 
Chapter 2 Materials and Methods 
2.1 Recombinant D N A techniques 
2.1.1 Preparation of Escherichia coli strain DH-5a competent cells 
Appropiate strain of Escherichia coli (E.coli) DH-5a was streaked from a -70 
frozen stock onto the surface of an agar plate and incubated for 14 to 16 hours at 37 
Single colony from the plate was picked and inoculated into 10 ml LB medium 
and incubated at 37 °C at 250 rpm for 2 hours. The culture was added to 100 ml LB 
medium and continued shaking at 37 °C at 250 rpm until OD600 reached 0.4 to 0.5 
until (about 2 hours), with cell density of 4-7 x 10^ cells/ml. Then the culture was 
chilled in ice for 15 minutes and centrifuged at 2000 g for 15 minutes at 4°C. The 
supernatant was discarded and the pellet was resuspended in 33 ml of RFl and then 
kept on ice for 15 minutes. The bacterial suspension was centrifuged again at 2000 g 
for 15 minutes at 4 °C. Then the cell pellet was resuspended in 8 ml RF2 and chilled 
in ice for 15 minutes. The cells were then aliquoted into 1.5 ml eppendorf tubes in 
100 [x\ per tube and frozen in liquid nitrogen. The cells were then stored in -70 °C 
until use. The transformation efficiency of the competent cells was assessed by 
transforming 1 ng of pUC19 plasmid and spread 1/10 of the total cells on LB A plate. 
The efficiency was calculated by number of colony formed when 1 |.ig of D N A was 
transformed into the cell. 
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2.1.2 Transformation of plasmid DNA into competent cells 
A frozen tube containning about 100 |LI1 competent cells was thawed in ice bath. 
Plasmid of interested D N A (1-lOng) was added into the competent cells, mixes and 
kept chilling on ice for 30 minutes. The mixture tube was then heat-shocked by 
transferring into a 42°C water bath and incubated for 2 minutes. Then the tube was 
again chilled in ice rapidly for 10 minutes. Appropriate amount of cells was spread 
evenly onto a LB plate with antibiotic according to the resistance conferred by the 
transformed plasmid. The plate was place inverted in a 37°C incubator for 16 hours 
to obtain plasmid-containing colonies. 
2.1.3 Preparation of plasmid DNA using QIAGEN Plasmid Maxipreps kit 
Procedures and solutions were essentially those provided by the manufacturer. A 
single colony of bacteria on a LB agar plate with appropriate antibiotic was 
inoculated into 250 ml LB medium containing appropriate antibiotic. The medium 
was incubated for 16 hours at 37°C at 250 rpm. Bacterial pellet was collected by 
centrifugation at 6,000 g for 15 minutes at 4°C. The cell pellet was totally 
resuspended in 10 ml of Buffer PI containing 100 \xg/ml RNase. Then 10 ml of 
Buffer P2 was added and mixed gently to the suspension and incubated for 5 
minutes at room temperature. 10 ml of P3 was added to the mixture which was then 
chilled on ice for 15 minutes. Cell debris and chromosomal D N A were removed by 
centrifugation at 20,000 g for 30 minutes. During the 30 minutes, a QIAGEN-Tip 
500 was added with 10 ml Q B T buffer and drained by gravity flow. After the 
precipitation was spun down, the cleared supernatant was transferred to the 
equilibrated column. After the lysate had passed through the column, the column 
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was washed with 2x 30 ml of Q C buffer. By adding 15 ml of QF buffer, the plasmid 
D N A adsorbed in the matrix was then eluted. The eluted plasmid D N A was then 
precipitated with 10.5 ml (0.7 volume) of room temperature isopropanol and 
centrifuged immediately at 15,000 g for 30 minutes at 4°C. The supernatant was 
discarded carefully not to disrupt the chalky white D N A pellet. Then the pellet was 
washed with 75% ethanol at room temperature and was recovered by centrifugation 
at 15,000 g for 10 minutes. The plasmid D N A was then air dried and dissolved in 
TE or sterile water with desired volume. 
2.1.4 Phenol/ chloroform extraction of DNA 
D N A sample dissolved in water or TE was added with a phenol / chloroform/ 
isopropanol mixture with a ratio of 25: 24: 1 by volume. The mixture was then 
vigorously mixed by vortexing and shaking and then incubated at room temperature 
for 10 minutes. The mixture was centrifuge at 12, 000 g for 10 minutes at 4°C. The 
aqueous phase containing the D N A was extracted to a fresh tube and then 
precipitated by ethanol precipitation. Two volumes of ice-cold absolute ethanol was 
added to D N A solution. The tube was incubated at -70。C foe 30 minutes. The D N A 
was pellet by centrifugation at 12,000 g for 10 minutes. The pellet was washed with 
75% ethanol at room temperature and redissolved in desired amount of TE or sterile 
water. 
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2.1.5 Spectrophotometric quantitation of the amount and purity of DNA 
Spectrophotometric was used for quantition of nucleic acid. 1 O D unit at 260 nm 
corresponds to 50 |<ig/ml double-stranded DNA, 40 |_ig/ml single stranded D N A , or 
20 |Lig/ml single stranded oligonucleotides. Small amount (1-10 |LI1) of D N A sample 
was diluted in 200-1000 |LI1 water. The diluted D N A sample was transferred to a 
quartz curette with water as blank. The sample was read at O.D. 260 nm and 
adjusted the reading in the range 0.1-1 by increasing or decreasing the diluted 
sample factor of the sample. The purity of D N A sample could be determined by the 
ratio of its absorbance at O.D. 260nm and 280 nm. If the ratio is 1.8 or above, the 
D N A sample was considered to be pure and suitable for transfection. 
2.2 Drugs preparation 
2.2.1 Preparation of aqueous extracts of Danshen 
Danshen bought from “北京同仁堂” was cut into small pieces and mortared into 
powder form. lOg of Danshen powder were refluxed in 50 ml distilled water for 1 
hour. The resin was discarded and the supernatant was filtered through a 0.2-^m 
filter. The filtrate was then lyophilized into dried powder. 
2.2.2 Preparation of ethanol extracts of Danshen 
lOg of Danshen powder was mixed with 50 ml methanol with constant shaking in 
room temperature for 16 hours. The resin was discarded and the supernatant was 
filtered through a 0.2-|Lim filter. The filtrate in a falcon tube was placed into a 70 °C 
water bath for 5 hours to evaporate most of the methanol. The remaining moist of 
the extract was dried by lyophilization. 
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2.3 3-(4,5-dimethylthiazoI-2-yl)-2, 5-diphenyI-tetrazoIium (MTT) 
assay 
1 X 10)4 cells/well was seeded in 100 jitl of culture medium in a 96-well culture plate 
and kept in a humidified atmosphere of 5% (v/v) C02at 37°C for 18 hours. After 
incubation, 100 ixl culture medium is discarded. Drugs were diluted to the 
appropiate concentration with culture medium to a final volume of 100 ^il and were 
added to the well and incubated at 37 5% CO2 for 18 hours. Cells alone were 
used as a control and medium alone was used as a blank. 30 \il of M M T solution 
(15mg/ml) was added to the well and incubated at 37 °C for 2 hours. After removing 
all M T T in the well, 100 |LI1 of D M S O was added to dissolve any crystals formed 
during reduction of M T T by living cells. The plate was shaken briefly and was read 
by a microplate reader (Bio-Rad, Model 3550) at absorbance 540 nm. 
2.4 Analysis of proteins from culture cells 
2.4.1 Extraction of total proteins from culture cells 
Before cell harvesting, appropriated amount of PBS (0.8-1 ml per well) was added 
into 12-well plate to wash the cells. When the cells were grown to about 80% 
confluence, 100 \xl of the Ix lysis buffer was added in order to attain the protein 
concentration of around 1-3 jug/^il and then incubated for 10 minutes. Cell extract 
was transferred to eppendorf tube and was then centrifuged at 12,000 g for 10 
minutes at 4°C. The supernatant was transferred to a fresh tube and ready for use or 
storage at -70°C. 
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2.4.2 Quantitation of protein by Bradford method 
A protein standard curve was set up by preparing 0，2, 4, 6, and 8 jug/ml of purified 
B S A in volume of 0.8 ml. Similarly, appropriate amount of protein sample was 
diluted by water to 0.8 ml. Then, 0.2 ml of 5x Bradford reagent (Bio-Rad) was 
added to each tube. The tubes were mixed immediately and incubated for 5 minutes. 
As judged by naked eyes, when the intensity of sample tube was over than that of 
protein standards, less protein should be used. 0 \ig/m[ B S A used as a blank. After 5 
minutes, the standard BSA and the sample were transferred to 1 ml plastic cuvettes 
and reading at the absorbance at 595 run by using spectrophotometer. The standard 
curve can then be plotted and so the concentration of each sample can then 
determined. 
2.4.3 Protein separation by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out according to Laemmi (1970). The Mini-PROTEIN® II 
electrophoresis cell (Bio-Rad) was used. The percentage of polyacrylamide in the 
mixture might be varied according to desired range of protein molecular weight. 
Generally 10% gel was applicable to most purposes. The volume of the 
resolving-gel mix needed per gel was about 3.2 ml if 0.75 m m thickness gel was 
made (Table la). After the gel solution pipetted to the gel gap at one side, 100 ix\ of 
isopropanol was added to remove air bubbles and to flatten the edge of the gel. 
After 30 minutes polymerization of the gel，isopropanol was removed from the gel 
top. Then the stacking-gel mix (Table lb) was pipetted on top of the running gel and 
the comb for sample slots was inserted into the stacking-gel layer immediately. The 
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gel was ready to use after 20 minutes. The gel setup was put in the gel-tank. Fresh 
SDS-PAGE running buffer was poured to the cavity formed by electrode-unit and to 
the surrounding space. Protein sample were mixed with SDS sample loading buffer 
and heated at 95 for 5 minutes. Appropriate denatured sample was loaded and the 
gel was run at 120V. 
Table la Solutions for preparing 10% running gel for SDS-PAGE. 
Solution components 10% running gel 
Distilled water 2.5 ml 
30% Acrylamide mix 2.5 ml 
4x SDS resolving buffer, pH 8.8 1.95 ml 
10% APS 0.1 ml 
T E M E D 47a 
Table lb Solutions for preparing 2.5% stacking gel for SDS-PAGE. 
Solution components 10% running gel 
Distilled water 2 ml 
30% Acrylamide mix 0.6 ml 
4x SDS resolving buffer, pH 6.8 0.89 ml 
10% APS 507U 
T E M E D T^l 
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2.4.4 Western blot analysis 
After electrophoresis, the stacking was discarded and the size of the resolving gel 
was measured (usually 5 x 8 cm ) and equilibrated in transfer buffer for 15 minutes 
or more. P V D F nitrocellulose membrane (Millipore) and 6 pieces of Whatman 
3-mm filter paper were cut to slightly large size than the gel. For P V D F membrane, 
it was presoaked in methanol for 3 minutes and then equilibrated in transfer buffer 
for 15 minutes or more. The 3 m m filter paper were stacked into two stacks of 3 
pieces and wetted with transfer buffer. 
Electroblotting was carried out using a semi-dry electroblotter Trans-Blot Cell 
(BioRad). The gel put on top of the membrane was put between 2 stacks of prepared 
filter papers each composed of 3 pieces. The semi-dry blotting was operated at a 
constant voltage of 10 V for 1 hour. Then the membrane was removed and kept wet 
in TBST solution. To block the non-specific binding of antibodies to the membrane, 
it was immersed in blocking solution (5% non-fat milk in TBST) and shaken for 1 
• hour at room temperature. Antibody of appropriated dilution was applied to the 
membrane and incubated at 4°C for 16 hours with constant shaking. The membrane 
was then washed in TBST solution for 3 times each for 15 minutes. Appropriate 
secondary antibody conjugated with horseradish peroxidase (HRP) was diluted in 
TBST in a concentration suggested by manufacturer with the membrane at room 
temperature for 1 hour, followes by washing in TBST solution for 3 times each for 
15 minutes. E C L ™ (enhanced chemiluminescence) detection kit (Amershan 
Pharmacia Biotech) was used to obtain signal from the membrane. The membrane 
was exposed to Hyperfilm™ E C L ™ (Amershan Pharmacia Biotech) at certain time 
intervals (lOseconds to 20 minutes). 
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2.5 Reagents and buffers 
2.5.1 Reagents for competent cell preparation 
LB (Luria-Bertani) medium 
10 g bacto-tryptone, 5 g yeast extract, 10 g NaCl. 
The solution was made up to 1 liter with distilled water and sterilized by autoclave 
LBA medium 
LB medium was supplemented with filtered stock ampicillin solution (100 mg/ml) 
to a final concentration of 50 ixg /ml in sterile condition. 
Agar media 
Liquid media were prepared according to the recipes given above. 15 g of 
bacto-agar was added to 1-liter liquid medium and autoclaved. 
RFl 
30 m M KAc, 100 m M RbCb，10 m M CaCh，50 m M MnCh, 15% glycerol. pH was 
adjusted to 5.8 by NaOH. Sterilized by filtration through 0.2-|_im filter. 
RF2 
10 m M MOPS, 75 m M CaCb, 10 m M Rb CI CaCk，15% glycerol. The solution was 
adjusted to pH 6.8 with N a O H and was filtered sterilze. 
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2.5.2 Reagents provided by QIAGEN Plasmid Maxipreps kit 
PI 
50 m M Tris-base, 10 m M EDTA. Sterilized by autoclave foe 20 minutes, then added 
RNase A to final concentration of 100 ^ il/ml. Stored at 4°C. 
P2 
0.2 M NaOH，1% SDS. Sterilized by autoclave for 20 minutes. 
P3 
3 M potassium acetate (pH 5.5). Sterilized by autoclave for 20 minutes. 
QBT 
50 m M MOPS, pH 7.0，0.75 M NaCl, 15% isopropanol, 0.15% Triton® X-100. 
Sterilized by filtration through 0.2 [xM filter. 
QC 
50 m M MOPS, pH 7.0，1 M NaCl, 15% isopropanol. Sterilized by filtration through 
0.2 i M filter. 
QF 
50 m M Tris-base, 1.25 M NaCl, 15% isopropanol. Sterilized by filtration through 
0.2 |LIM filter. 
2.5.3 Reagents for SDS-PAGE 
SDS-electrophoresis buffer (5x stock solution) 
15.1 gTris base (0.125 M ) 
72 g glycine (0.96 M) 
5 g SDS (0.5% (w/v)) 
Distilled water was added to 1 liter. 
SDS-electrophoresis buffer (Ix working buffer) 
The buffer was prepared from 5x stock solution. 
SDS-PAGE loading buffer (2x) 
100 m M Tris-HCl，pH 6.8，200 m M DTT, 4% SDS, 0.2% bromophenol blue, 20% 
glycerol. Stored at -20 °C for long term storage or 4 °C for short term. 
4x SDS resolving buffer, pH 8.8 
18.17 g/100 ml Tris base 
0.8 g/100 ml SDS or 4 ml/100 ml 10% SDS 
pH was adjusted to 8.8 with HCl. Stored at 4°C. 
4x SDS resolving buffer, pH 6.8 
6.06 g/100 ml Tris base 
0.8 g/100 ml SDS or 4 ml/100 ml 10% SDS 




10% glacial acetic acid 
0.25% (w/v) Comassie Brilliant Blue R250 




10% glacial acetic acid 
2.5.4 Reagents and buffers for Western blotting 
Transfer buffer 
2.9 g/L glycine (39 m M ) 
5.9 g/L Tris base (48 m M ) 
0.37 g/L SDS (0.037%) 
200 ml/L methanol (20%) 
Stored at 4 
TBS(10x stock solution) 
24.2 g/L Tris base 
80 g/L NaCl 
pH was adjusted to 7.6 with HCl. Stored at 4 
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TBST 
100 ml of lOx TBS was added to 900 ml of distilled water. 1 ml ofTween 20® was 
added and stirred. Stored at 4 °C. 
2.5.5 Cell lines 
Cos-7 cells 
Cos-7 cells are purchased from American Tissue and Cell Culture (ATCC # 
CRL-1651) is a monkey kidney cancer cell line. They were maintained in D M E M 
(Invitrogen) supplemented with 10 FBS and 1% penicillin and streptomycin 
(Invitrogen). 
CHO-Kl cells 
CHO-Kl cells are purchased from American Tissue and Cell Culture (ATCC # 
CCL-61) is a Chinese hamster ovary cancer cell line. They were maintained in 





Clone name *P- tau residue(s) Source Working 
dilution 
HT^7 (mAb) Nil Innogenetics 1 :500 
T ^ ( m A b ) —Nil D A K O 1:500 
'M-HO (mAb) 一 Thr 181 Innogenetics T: 500 — 
AT-180 (mAb) Thr231 — Innogenetics 1 : 250 
AT-8 (mAb) S^202 一Innogenetics 1 : 100 
PHF-1 (mAb) Ser 396, Ser 404 Dr. P. Davies- 1 : 500 
KOtvos et aL, 1994) 
P-tau residue(s) refer to phosphorylated residues on tau recognized by the 
antibodies. 
Other antibodies 
Clone name Protein recognized Source Working 
dilution 
GSK-3(3 (mAb) GSK-3p Transduction Laboratory 1 : 2000 
Cdk-5 (mAb) Cdk-5 Santa Cruz Technology "l : 500 — 
(mAb) |p35 |Santa Cruz Technology 11 : 500 
2.5.7 Plasmids 
Plasmids including human glycogen synthase kinase -3p and tau 0N3R cDNAs 
subcloned in pCIneo mammalian protein expression vector (Promega), pCIneo-
GSK-3p and pCIneo- TauONSR, were used in transient transfection in Chapter 3. 
p C M V neo- Cdk-5 and p C M C neo- p35 were a gift from Dr. K.F. Lau (Institute of 
Psychiatry, University of London), were also used in transient transfection in 
Chapter 4. 
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2.5.8 Other Chemicals 
Protocatechualdehyde (PCAH) was purchased from Wako Chemical Company, 
Japan. 
Salvianolic acid B (SAB) was purified from Mr. P.M. Hon, Institute of Chinese 
Medicine, The Chinese University of Hong Kong. 
Roscovitine was purchased from the Sigma Chemical Company. 
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Chapter 3 The effect of Danshen on GSK-3 induced 
hyperposphorylation of tau in Cos? cells 
3.1 Introduction 
3.1.1 Glycogen synthase kinase-3 (GSK-3) 
GSK-3 is a proline-directed serine/threonine kinase, which was originally found to be 
able to phosphorylate at the sites 3a and 3p of glycogen synthase and thereby 
inactivate it (Embi et al., 1980; Hughes et aL, 1993; Skurat and Roach，1995). It is 
also a kinase (Hemmings et al., 1981) that can phosphorylate nuclear transcriptional 
factors and cytoplasmic protein. Genetic analyses in Drosophila (Ruel et al” 1993) 
and Xenopus (He et a!., 1995) both indicated that GSK-3 involves in controlling the 
development of body pattern. 
3.1.2 Structure of GSK-3 
GSK-3 was first purified to homogeneity from skeletal muscle (Woodgett and Cohen, 
1984)，and molecular cloning revealed that there were two closely related isoforms, 
GSK-3 a and GSK-3 (3，which are expressed ubiquitously in mammalian tissues 
(Woodgett, 1990; Woodgett, 1991). GSK-3 a and GSK-3 P are encoded from two 
distinct genes with molecular weights of 51 and 47 kDa, respectively. The proteins 
share 97% sequence similarity within their kinase catalytic domains, but differ 
significantly from each another outside this region, with GSK-3 a possessing an 
extended N-terminal glycine-rich tail (Frame and Cohen, 2001). 
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GSK-3 is phylogenetically closely related to the cyclin-dependent protein kinases, 
such as cdc2. However, the specificity of GSK-3 is unique and the optimal consensus 
site for phosphorylation being Ser/Thr-Xaa-Xaa-Xaa-pSer/pThr (where pSer and pThr 
are phosphoserine and phosphothreonine, respectively and Xaa is any amino acid) 
(Fiol et al, 1987). This motif is found in several well-established substrates of GSK-3, 
such as glycogen synthase, the s-subunit of eIF2B (Welsh and Proud, 1993; Welsh et 
al., 1998), and ATP citrate-lysate (Hughes et al., 1992; Benjamin et al, 1994). 
Besides, it requires a priming phosphate at n + 4 (where n is the site of 
phosphorylation by GSK-3) in order to phosphorylate many of its substrates (Fiol et 
al., 1987). 
GSK-3 is one of the few protein kinases that are inactivated by phosphorylation. In 
unstimulated tissue-culture cells or rabbit skeletal muscle, GSK-3 is phosphorylated at 
one tyrosine residue (Tyr 216 in GSK-3P; Tyr279 in GSK-3a), and dephosphorylation 
of this residue, reduces activity in vitro (Hughes et al,, 1993). Mammalian GSK-3(3, 
which is bacterially expressed show that it is capable of phosphorylating itself on 
tyrosine as well as serine and threonine residues, suggesting that GSK-3 itself may be 
responsible for the phosphorylation of Tyr216 in mammalian cells (Frame and Cohen, 
2001). 
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3.1.3 The importance of GSK-3 in AD 
Hyperphosphorylated tau is the major component of the paired helical filaments 
(PHFs) and neurofibrillary tangles (NFTs) found in the brains of A D patients (Goedert, 
1993; Duyckaerts et aL, 1998b; Duyckaerts et al., 1998a). PHF-tau is phosphorylated 
on at least 25 sites (for review, Billingsley and Kincaid, 1997) and GSK-3p, also 
known as tau protein kinase I (TPK 1) (Ishiguro et al” 1993)，is one of the best 
candidate enzymes for generating the hyperphosphorylated tau (Lovestone et al., 
1994). 
GSK-3P is interesting in the context of A D research because it phosphorylates tau 
efficiently at Ser/Thr-Pro motifs that are elevated in A D (Hong et al., 1997; Singh et 
al” 1995; Zheng-Fischhofer et al, 1998). GSK-3p is found in the microtubule protein 
fraction of rat and bovine brain extract which can phosphorylate native tau that is 
isolated from the normal brain and is already phosphorylated to some extent, but 
cannot act on completely dephosphorylated tau (Imahori et al., 1998). It 
phosphorylates in closely spaced pairs, in the order S396/S404，S46/T50, and 
S202/T205 followed by the others. The first and the third pair are epitopes of 
antibodies PHF-1 and AT-8 respectively (Godemann et aL, 1999). Evidence also show 
that GSK-3(3 is involved in the formation of PHF (Shiurba et al., 1996; Plyte et aL, 
1992). 
The Wnt signaling pathway is implicated in interaction and processing of presenilin 1 
(PSl) whose missense mutations are linked to familial AD. PSl interacts with 
P-catenin, GSK-3(3, and tau protein and these interactions are modified in the familial 
A D mutations of PSl (Takashima et al., 1998; Zhang et al., 1998; Zhou et aL, 1997). 
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Besides, Ap-induced neurotoxicity is thought to be mediated by GSK-3(3 (Takashima 
et al., 1995). 
Apart from these, GSK-3p also phosphorylates pyruvate dehydrogenase (PDH) which 
finally results in its inactivation (Perry et al., 1977; Sorbi et al., 1983; Yates et al., 
1990). Since P D H is a key enzyme in the glycolytic pathway, its activation will have 
many serious consequences. It will result in failure of the T C A cycle and of ATP 
production. These finally result in dysfunction of glucose metabolism and contribute 
to neuronal death through energy failure. And the accumulation of lactate will occur 
and result in acidosis, as is actually seen in A D brain. However, the most serious 
effect will be the inhibition of acetylcholine synthesis. This would affect cholinergic 
neurons, and might easily lead to loss of memory and cognitive ability, which is 
characteristic of A D (Imahori and Uchida, 1997). 
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3.2 Materials and Methods 
3.2.1 Transfection of Gsk-3 and tau into Cos? monkey kidney cells 
Cells were plated at sub-confluent density in a 12-well plate before transfection. 
According to the manufacturer's instruction, the amount of FuGene™ 6 reagent per 
well was 2 |j.l and the total amount of D N A per well was 0.6 |ig. For transfection per 
24mm well, 2 of transfection reagent was diluted in 65 of D M E M S F M and 
incubated for 5 minutes. 0.3 昭 of pCIneo-GSK-3p and 0.3 昭 of pCIneO-TauON3R 
was added in a new eppendorf. After 5 minutes, the diluted transfection reagent was 
added dropwisely into the tube containing D N A without touching the tube wall and 
the mixture was incubated for 30 minutes. Then 60 jiil per well of the mixture was 
dropped evenly to the plated cells and the plate was returned to the CO2 incubator at 
37 °C. For the treatment of Danshen and its active components, different 
concentrations (80 fig/ml, 40|ag/ml and 20 |Lig/ml) was added after the transfected 
cells were washed with two times PBS at 18 hours post-transfection. In the case of 
negative control, 3 0 m M LiCl was used to inhibit the kinase activities. The cells were 
harvested at 36 hours post-transfection. 
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3.2.2 Extraction of total proteins from culture cells 
The detail can be referred to Chapter 2 (2.4.1). 
3.2.3 Quantitation of protein by Bradford method 
The detail can be referred to Chapter 2 (2.4.2). 
3.2.4 Protein separation by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
The detail can be referred to Chapter 2 (2.4.3). 
3.2.5 Western blot analysis 
The detail can be referred to Chapter 2 (2.4.4). 
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3.3 Results 
3.3.1 Toxicity test on Cos? cells 
Table 3.1 shows the extraction yield of aqueous and ethanol extracts of Danshen and 
the yield of extraction of aqueous and ethanol extracts were 86 % and 15% 
respectively. Protocatechualdehyde (PCAH) was purchased from Wako Chemical 
Company, Japan. For the other aqueous active component, salvianolic acid B (SAB), 
it was kindly purified by Mr. P.M. Hon. Estimated by HPLC chromatography, there 
are 0.05% of PCAH and 25% SAB in aqueous extract of Danshen. 
As shown in Fig. 3.1, the crude extract of Danshen (aqueous extract and ethanol 
extract) exhibit 50% cell death at 320 ^ ig/ml. PCAH has the highest toxicity to Cos7 
that causes 50% cell death at concentration of 160 |ig/ml. However, SAB has no 
toxicity and instead at concentration 160 |ig/ml it increased 20% cell growth. 
3.3.2 The effect of ethanol extract of Danshen on GSK-3P induced tau 
phosphorylation 
In Fig. 3.2，30 m M lithium chloride (LiCl) was used to inhibit GSK-3P to 
phosphorylate tau, no hyperphosphorylated tau protein was detected by using AT-180 
and AT-270 antibodies. Serum free medium was used as a positive control to indicate 
the maximum activity of GSK-3P for phosphorylating tau. A stack of tau bands 
ranging approximately from 46 to 54 kDa was found. The tau bands were attributed to 
the different degree of phosphorylation of tau. When compared with the positive 
control, sample treated with ethanol extract of Danshen blotted with AT-180 decreased 
and in band intensity whilst no significant effect was found in the AT-270 blot. 
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Table 3.1 Extraction yields of Danshen extracts under reflux and soaking system. 
Crude extract of Dansher Extraction method Raw material (g)Extract (g)Extraction yield {%] 
Aqueous extract Reflux soaking 10 8.6 86 
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Fig. 3.1 Toxicity test of Danshen and its active components (protocatechualdehyde 
(PCAH) and salvionlic acid B (SAB)) on monkey kidney cell (Cos7). All data were 
expressed as mean 土 SD (n = 4). 
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3.3.3 The effect of aqueous extract of Danshen on GSK-3p induced tau 
phosphorylation 
By using different phosphorylated tau antibodies (AT-180, AT-270, AT-8 and PHF-1), 
effects of aqueous extract on GSK-Sp induced tau phosphorylation were evaluated. 
For the blots applied with AT-270, a significant reduction in band intensity was found. 
Total loss of immunoreactivity was found in AT-180 blot (Fig.3.3). As shown in Fig. 
3.4，there was no phosphorylated tau detected in the blot applied with AT-8 and 
PHF-1, therefore aqueous extract reduces GSK-Sp kinase activity on tau 
phosphorylation. 
The plasmids of GSK-Sp and tauONSR were over-expressed in Cos7 cells (Fig. 3.5). 
In the blot with GSK-Sp antibody, a single band is located at 46 kDa despite of 
various treatment conditions. For the blot applied with a HT-7 antibody, stack of 
bands was found. For the LiCl treatment, a down shift of the tau band was found. 
3.3.4 The effect of Protocatechualdehyde on GSK-3p induced tau 
phosphorylation 
As observed in the positive control (Fig. 3.6 and 3.7), transfection of GSK-3[3 and 
tauONSR into Cos7 cells caused hyperphosphorylation of tau as seen in lanes of. 
Treatment of LiCl, totally inhibited the kinase activity thus there was no 
phosphorylated tau blotted by AT-180，AT-270, AT-8 and PHF-1 antibodies (Fig. 3.6 
and 3.7). Protocatechualdehyde (PCAH) is one of the active components purified 
from the aqueous extract of Danshen. P C A H was found to reduce the amount of tau 
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phosphorylation by GSK-Sp in a dose-dependent manner ranging from 8 |Lig/ml to 80 
|Ltg/ml. However, in the AT-180 blot, the 40 |uig/ml bands are less intense than the 80 
|ig/ml of PCAH. It reduces the amount of GSK-3p expression and the amount of total 
tau expression as shown in the blots using GSK-3p and HT-7 respectively (Fig. 3.8). 
3.3.5 The effect of Salvianolic acid B on GSK-3P induced tau 
phosphorylation 
Apart from PCAH, Salvianolic acid B (SAB) is also an aqueous active component of 
Danshen. As shown in Fig. 3.9 and 3.10, the blots applied with different 
phosphorylated tau antibodies (AT-180，At-270, AT-8 and PHF-1), band intensity was 
highly reduced after SAB treatment at different concentration ranging from 8 |_Lg to 80 
l^ g. Apart from the blot applied with AT-270 and PHF-1, the effect of SAB on 
inhibiting GSK-Sp-induced tau phosphorylation is dose dependent. After 16 hours 
treatment of SAB, the expression of GSK-Sp and total tau were not affected (Fig. 
3.11). 
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Fig. 3.2 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauON3R and GSK-3p (tau + GSK-3P) and blotted with antibodies (A) AT-180 and (B) 
AT-270. Cells were treated with SFM and 30mM LiCl as a positive (+VE) and 
negative (LiCl) control respectively. 80 jug of 95% ethanol extract (EtOH extract) was 
added at 36 hours post-transfection. Two replicas were performed for the control and 
three replicas for Danshen treatment. The arrows show the relative position of 49kDa, 
at which tau was located. 
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Fig. 3.3 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauON3R and GSK-3P (tau + GSK-3P) and blotted with antibodies for (A) AT-180 
and (B) AT-270. Cells were treated with SFM as a positive (+VE) control. 80 ^ xg of 
aqueous extract (Aq. extract) was added at 36 hours post-transfection. Two replicas 
were performed for the control and three replicas for Danshen treatment. The arrows 
show the relative position of 49kDa, at which tau was located. 
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Fig. 3.4 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauON3R and GSK-3 p (tau + GSK-3 P) and blotted with antibodies for (A) AT-8 and 
(B) PHF-1. Cells were treated with SFM as a positive (+VE) control. 80 |Lig of 
aqueous extract (Aq. extract) was added at 36 hours post-transfection. Two replicas 
were performed for the control and three replicas for Danshen treatment. The arrows 
show the relative position of 49kDa, at which tau was located. 
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Fig. 3.5 Tau phosphorylation of transfected Cos? cell. Cells were transfected with 
tauON3R and GSK-Sp (tau + GSK-3P) and blotted with antibodies for (A) GSK-3(3 
and (B) HT-7. Cells were treated with SFM as a positive (+VE) control. 80 |Lig of 
aqueous extract (Aq. extract) was added at 36 hours post-transfection. Two replicas 
were performed for the control and three replicas for Danshen treatment. The arrows 
show the relative position of 49kDa, at which GSK-3P (47kDa) and tau were located. 
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Fig. 3.6 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauON3R and GSK-3P and blotted with antibodies for (A) AT-180 and (B) AT-270. 
Cells were treated with SFM and 30mM LiCl as a positive (+VE) and negative 
control (LiCl) respectively. Different concentrations of PCAH (80 |Lig/ml, 40 |ig/ml 
and 8 jug/ml) were added at 36 hours post-transfection. Two replicas performed. The 
arrows show the relative position of 49kDa, at which tau was located. 
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Fig. 3.7 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauON3R and GSK-3 p and blotted with antibodies for (A) AT-8 and (B) PHF-1. Cells 
were treated with SFM and 30mM LiCl as a positive (+VE) and negative control 
(LiCl) respectively. Different concentrations of PCAH (80 jug/ml and 20|Lig/ml) were 
added at 36 hours post-transfection. Two replicas were performed. The arrows show 
the relative position of 49kDa, at which tau was located. 
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Fig. 3.8 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauON3R and GSK-3p and blotted with antibodies for (A) GSK-3(3 and (B) HT-7. 
Cells were treated with SFM and 30mM LiCl as a positive (+VE) and negative 
control (LiCl) respectively. Different concentrations of PCAH (80 |Lig/ml, 40 |Lig/ml 
and 8 |Lig/ml) were added at 36 hours post-transfection. Two replicas were performed. 
The arrows show the relative position of 49kDa, at which GSK-3 p (47kDa) and tau 
was located. 
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Fig. 3.9 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauONSR and GSK-3P and blotted with antibodies for (A) AT-180 and (B) AT-270. 
Cells were treated with SFM and 30mM LiCl as a positive (+VE) and negative (LiCl) 
control respectively. Different concentrations of SAB (80 ^ig/ml, 40 )j,g/ml and 8 
p,g/ml) were added at 36 hours post-transfection. Two replicas were performed. The 
arrows show the relative position of 49kDa, at which tau was located. 
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Fig. 3.10 Tau phosphorylation of transfected Cos? cells. Cells were transfected 
with tauON3R and GSK-3 p and blotted with antibodies for (A) AT-8 and (B) PHF-1. 
Cells were treated with SFM and 30mM LiCl as a positive (+VE) and negative (LiCl) 
control respectively. Different concentrations of SAB (80 |xg/ml, 40 fxg/ml and 8 
fig/ml) were added at 36 hours post-transfection. Two replicas were performed. The 
arrows show the relative position of 49kDa, at which tau was located. 
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Fig. 3.11 Tau phosphorylation of transfected Cos? cells. Cells were transfected with 
tauONSR and GSK-3P and blotted with antibodies for (A) GSK-3P and (B) HT-7. 
Cells were treated with SFM and 30mM LiCl as a positive (+VE) and negative (LiCl) 
control respectively. Different concentrations of SAB (80 |ig/ml，40 |j.g/ml and 8 
i^g/ml) were added at 36 hours post-transfection. Two replicas were performed. The 




Before testing Danshen extracts and its aqueous active components on GSk-3P 
phosphorylation of tau (PCAH and SAB), the highest concentration of these 
components that does not cause cell death was determined. Ethanol and aqueous 
crude extracts of Danshen caused more than 50% cell death at the concentration of 
320 |j,g/ml. The highest concentration that showed no toxicity was 80 |Lig/ml and this 
concentration was finally used for treating cells. PCAH, it nearly killed all cells at 320 
|Lig/ml and caused 50% cell death at 160 )ig/ml. On the other hand, 80 |_ig/ml of PCAH 
did not show toxicity to Cos-7. SAB was another aqueous active component used for 
cell treatment, it had no toxicity to Cos7 but it increased cell proliferation at high 
concentration. Therefore, 80|j,g/ml was also used. 
In this study, mammalian Cos? cells were transiently transfected by GSK-Sp and 
tau.In this way, tau was phosphorylated by GSK-3p at many of the sites we observed 
in A D brain. Lithium chloride (LiCl) is an effective inhibitor of GSK-3p (Kelin and 
Melton, 1996) and the IC50 of LiCl on the activity of GSK-3P towards tau was about 2 
m M . More than 80% of the GSK-Sp activity was inactivated by 20 m M of lithium 
monovalent cations. Therefore, LiCl was used as a negative control. 
Upon treatment of ethanol extract of Danshen, slightly reduced of phosphorylation of 
tau at the sites of Thr 231 but no effect at the Thr 181 was observed (Fig. 3.1) 
(immunoblots applied with ATI 80 and AT270 respectively). The expression level of 
GSK-3P and the smallest tau isoform 0N3R in Cos7 cells was not affected was not 
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affected after drug treatment (Fig. 3.4). GSK-3(3 phosphorylated predominantly 
Ser/Thr-Pro motifs in tau protein which occur in closely spaced pairs, in order 
Ser396/Ser 404，Ser45/Thr50 and S202/T205 followed by others. The first and third 
pairs are epitopes of antibodies PHF-1 and AT-8 and later on ThrlSl which are 
epitope of AT-270. After phosphorylation by GSK-3p，the M r of tau tends to shift 
upwards, depending on the combination of phosphorylation sites (e.g. phospho-Ser 
404 induces a noticeable shift) (Godemann et al., 1999). 
Antibody Band intensity Phosphorylation site(s) 
AT270 Reduced Reduced tau phosphorylation at T181 
ATI 80 No visible band Highly reduced tau phosphorylation 
atT231 
ATS No visible band Highly reduced tau phosphorylation 
at S202 
PHF-1 No visible band Highly reduced tau phosphorylation 
at S396 and S404 
Table 3.2 Summarized results on the phosphorylation of the tauON3R epitopes by 
GSK-3 p after treatment of aqueous extract of Danshen. 
After aqueous extract treatment, the band intensity of tau was reduced and the band 
also shift downward in the AT-270 blot (Fig. 3.2)，this indicate the reduce in tau 
phosphorylation at epitope T181. Also, no phosphorylated tau was detected at the 
sites of Thr231, Thrl81, Ser 202, Ser 396 and Ser 404 (Fig. 3.3 and 3.4). Table 3.1 
indicates that aqueous extract of Danshen exhibited suppression on GSK-3|3 induced 
61 
tau phosphorylation. Since it is a crude extract, and there may be some components in 
it which has powerful effect on reducing tau phosphorylation. Protocatechualdehyde 
is the aqueous active component purchased from Wako Chemical Company, Japan. 
For the other aqueous active component, salvianolic acid B，it was kindly purified by 
Mr. P.M. Hon. They are used for my further test. 
Both P C A H and SAB exhibited suppression on GSK-3p induced tau phosphorylation 
and the action was dose dependent. On the other hand, PCAH reduced the expression 
of GSK-Sp in a dose dependent manner. Therefore, the effect of PCAH on tau 
phosphorylation may not be due to reduction of kinase activity but due to reduction of 
the amount of expressed kinase. SAB did not reduce the amount of GSK-3p expressed, 
so it may reduce GSK-3(3 activities towards tau, or it may activate other phosphatase 
to reduce the phosphorylation of tau. In conclusion, SAB can protect tau from 
hyperphosphorylation and it may be explored to preventing the aggregation of 
PHF-tau. 
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Chapter 4 Cdk5 induced hyperposphorylation of tau 
in C H O cells 
4.1 Introduction 
4.1.1 Cyclin dependent kinase 5 (Cdk5) 
Cdk5 was discovered in the early 1990s, and is well known in regulating the 
cyto-architecture of the central nervous system (CNS). It functions prominently in the 
developing nervous system, and recent data also point to a role in synapse formation 
and neurotransmission. Recent evidence indicates that deregulation of this kinase is 
neurotoxic and involved in the pathology of neurodegenerative diseases, such as A D 
(reviewed by Dhavan and Tsai, 2001). 
4.1.2 Structure of Cdk5 
Cdk5 is a 33-kDa protein ubiquitously expressed in mammalian tissues and cultured 
cells. To be activated, Cdk5 has to associate with its regulatory subunit, p35. p35 is a 
35kDa protein identified as the first regulatory subunit of Cdk5 through its physical 
interaction with Cdk5 in brain lysates and by its ability to activate Cdk5 upon direct 
binding (Ishiguro et aL, 1994; Lew et aL, 1994; Tsai et al., 1994). p25, a truncated 
form of p35, accumulates in neurons in the brains of patients with Alzheimer's disease 
and plays a role in regulating cdk5. This accumulation correlates with an increase in 
Cdk5 kinase activity. Besides, p35 is expressed predominantly in neurons, implying 
that most cdk5 activity is concentrated in neuronal structures (Tsai et al., 1994; Lew et 
al., 1994). 
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Cdk5 also is involved in controlling cell differentiation in neuronal and muscle cells. 
Degeneration of cdk5 appears to be involved in neuronal degeneration according to 
studies in cellular models, an observation that may have implications in human brain 
disorders such as A D (Alvarez et al., 1999a; Lee et al., 2000). 
4.1.3 Neurological functions of Cdk5 
Cultures of cerebellar large neurons were used to study expression, subcellular 
localization and functions of neuronal Cdk5 activator during laminin-enhanced axonal 
growth. Lamini, an extracellular matrix component that promotes axonal extension 
stimulates p35 expression, thus increasing its interaction with subcortical cytoskeleton 
and its redistribution to axonal growth cones (Paglini et al., 1998; Ramirez et al., 
1999). From this study, the Cdk5 system appears to be an important regulatory link 
between extracellular signals such as laminin and intracellular organization of M A P s 
and other cytoskeletal proteins involved in axonal elongation (Paglini et al, 1998). 
Cdk5 is a proline-directed Ser/Thr protein kinase with postmitotic activity that 
phosphorylates KSP protein motifs on M A P lb, K S P X K on tau (Kobayashi et al, 
1993) or K S P X X on neurofilament proteins, actin-binding protein caldesmon and 
proteins of the synaptic vesicles (Sun et al., 1996; Shuang et al” 1998; Shetty et aL, 
1993). It contributes to phosphorylation of human tau on Ser202, Thr205, Ser235 and 
Ser404 (Michel et al., 1998). In addition to tau and other MAPs, Cdk5 phosphorylates 
the high molecular weight neurofilament proteins at their C-terminal domain 
(Maccioni et al., 2001). Cdk5 plays a pivotal role in neuronal development as 
evidenced by the abnormal corticogenesis and perinatal lethality of cdk5 knockout 
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mice (Ohshima et al” 1996) and the disturbances in neuronal migration and early 
death in p35 knockout mice (Chae et al., 1997). The Cdk5/p35 system participates in 
normal development of neuronal cells and the axonal growth (Paglini et al., 
1998;Pigino et al., 1997). Therefore, Cdk5 appears as one of the important kinases 
phosphorylating tau in neuronal cells. 
Cdk5 is deregulated in the brain of A D patients and it can also hyperphosphorylate tau 
and accumulates in tangle-bearing neurons (Patrick et al, 1999). It changes its 
cellular location and alters its substrate specificity after activating by p25 (Francis et 
al., 1999). In vivo the p25/Cdk5 complex hyperphosphorylates tau, which reduces the 
ability of tau to associate with microtubules. Moreover, expression of the p25/Cdk5 
complex in cultured primary neurons induces cytoskeletal disruption, morphological 
degeneration and apoptosis. These findings indicate that cleavage of p35, followed by 
accumulation of p25, may be involved in the pathogenesis of cytoskeletal 
abnormalities and neuronal death in neurodegenerative diseases (Kusakawa et al., 
2000). Apart from that, evidence based on studies of hipocampal cultures support the 
idea that in neurogeneration, the initial anomalous tau phosphorylation by Cdk5 
stimulate subsequent modifications by GSK-3 (3, thus preventing tau from 
incorporating into microtubules (Alvarez et al, 1999a; Sengupta et al., 1997; Alvarez 
et al., 1999b). 
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4.2 Materials and Methods 
4.2.1 Transfection of p35 and tau into CHO cells 
Cells were plated at sub-confluent density in a 12-well plate before transfection. 
According to the manufacturer's instruction, the amount of FuGene™ 6 reagent per 
well was 2 and the total amount of D N A per well was 0.6 |Ltg. For transfection per 
24mm well, 2 |LI1 of transfection reagent was diluted in 65 ^il of DMEM-F12 SFM and 
incubated for 5 minutes. 0.3 \ig of pCIneo-p35 and 0.3 昭 of pCIneO-TauON3R was 
added in a new eppendorf. After 5 minutes, the diluted transfection reagent was added 
dropwisely into the DNA's tube without touching the tube wall and the mixture was 
incubated for 30 minutes. Then 60 ^ il per well of the mixture was dropped evenly to 
the plated cells and the plate was returned to the CO2 incubator at 37 °C. In the case of 
negative control, roscovitine was used to inhibit the kinase activities. For the 
roscovitine treatment, different concentrations (30 m M , 20mM and 10 m M ) were 
added after the transfected cells were washed with SFM at 5 hours post-transfection. 
The cells were harvested at 21 hours post-transfection. 
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4.2.2 Extraction of total proteins from culture cells 
The detail can be referred to Chapter 2 (2.4.1). 
4.2.3 Quantitation of protein by Bradford method 
The detail can be referred to Chapter 2 (2.4.2). 
4.2.4 Protein separation by sodium dodecylsulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) 
The detail can be referred to Chapter 2 (2.4.3). 
4.2.5 Western blot analysis 
The detail can be referred to Chapter 2 (2.4.4). 
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4.3 Results 
4.3.1 Toxicity test on CHO cells 
As shown in Fig. 4.1, P C A H exhibited toxicity on C H O cells and caused about 50% 
cell death at concentration of 160 ]xg/ml On the other hand, SAB had no toxicity and, 
SAB increased 15% and 30% cell growth when applied at 160 jug/ml and 320 ^ g/ml 
respectively. Roscovitine is a potent inhibitor of Cdk5，has an IC50 value for Cdk5 at 
0.16 |j,M (Meijer et al, 1997). The toxicity of roscovitine to C H O cells is shown in 
Fig. 4.2, it only exhibited toxicity at the concentration higher than 20|j.M. There was 
no toxicity at 10 )_iM roscovitine treatment. 
4.3.2 Tau transfection in Cdk5/p35 and TauON3R transiently transfected CHO 
cells 
Fig. 4.3 shows endogenous Cdk5 expressing in cells with no transfection (NT) and 
transfected with tauON3R/p35 (p35). There were also significantly level of transient 
Cdk-5 and p35 expression of transfected plasmid in C H O cells (Fig.4.3). Tau 
phosphorylation was evaluated by immunblotting with HT-7，Tau (Fig. 4.3), AT-270, 
AT-8 or PHF-1 antibodies (Fig 4.4). The numerous tau band ranged approximately 
from 46 to 54 kDa were found in the immunoblots of different phospholated-tau 
antibodies. However, in the AT-270, AT-8, HT-7 and Tau blots (Fig. 4.3) indicate 
there are existences of non-specific band or endogenous tau-like protein. Undectable 
expression of endogenous tau was found in the lanes with no-transfection in the total 
tau (HT-7 and Tau) blot. 
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When transfecting tau and p35 into culture cells containing endogenous Cdk-5, 
phosphorylated tau was recognized by anti-tau antibodies. Blotting with HT-7 and tau 
antibodies, an up-shifl of band pattern and disappearance of the low molecular weight 
tau bands were found (Fig. 4.3-4.4). As shown in Fig. 4.4, the band intensity was 
increased in AT-270 blot in the top band of p35/tau transfected lanes. Up-shift of 
bands was also found in AT-8 blot (Fig. 4.4) when p35 was co-transfected with tau. 
Interestingly, PHF-1 detected a single tau with reduced band intensity was found in 
p35/ tau co-transfected lanes (Fig. 4.4). 
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Fig. 4.1 Toxicity test of Protocatechualdehyde and Salvianolic acid B on Chinese 
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Fig. 4.2 Toxicity test of Roscovitine on Chinese hamster cells (CHO) by using M T T 
assay. All data were expressed as mean 土 SD (n = 4). 
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Fig. 4.3 Tau phosphorylation of transfected CHO cells. NT is the control with no 
transfection. Cells were transfected with tauON3R + Cdk5 (CDK5) or tauON3R + p35 
(p35). (A)Endogenous and transient Cdk5 was immunobloted by Cdk5 Ab and (B) 
transient p35 was blotted by p35 Ab. Total tau proteins were blotted by using (C) 
HT-7 and (D)Tau antibodies. Two replicas were performed. The arrows show the 
relative position of 36kDa and 49kDa, at which Cdk-5 (33kDa), p35 (35kDa) and tau 
(46 to 54kDa) were located. 
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Fig. 4.4 Tau phosphorylation of transfected CHO cells. NT is the control with no 
transfection. Cells were transfected with tauON3R + Cdk5 (CDK5) or tauON3R + p35 
(p35). Phosphorylation of tau was blotted with antibodies (A) AT-270, (B) AT-8 and 
(C) PHF-1. Two replicas performed. The arrows show the relative position of 49kDa, 
at which phosphorylated tau (46 to 54kDa) was located. 
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4.3.3 Effect of roscovitine treatment on the transiently tau and p35 transfected 
CHO cells 
In Fig. 4.5 and 4.6，different concentrations of roscovitine were used to treat the cells 
transfected with tauONSR and p35, in order to find the concentration that can inhibit 
Cdk5 to phosphorylate tau. Fig. 4.5 shows that endogenous Cdk-5 expression level 
was not affect after the treatment of roscovitine. For the blot applied with p35，it 
showed that 20 and 30|_iM of roscovitine reduces the expression level of p35 (Fig. 4.5). 
At lO^M roscovitine, an up-shift of tau band was found in the blots applied with 
AT-270, HT-7 and Tau antibodies (Fig.4.6). However, highly reduced band density 
was found after 20^tM roscovitine treatment, and total loss of immunoreactivity was 
found at 30|.LM concentration. 
4.3.4 Effects of aqueous active components of Danshen, PCAH and SAB on the 
transiently tau and p35 transfected in CHO cells 
As observed in the positive control (Fig. 4.7), transfection of p35 and tauON3R into 
C H O cells caused hyperphosphorylation of tau and resulted in the upshift of bands. 
Treatment of roscovitine, inhibited the kinase activity thus there was downshift of 
bands in the blotted by AT-270, HT-7 and Tau antibodies (Fig. 4.7). 
Protocatechualdehyde (PCAH) is one of the active components purified from the 
aqueous extract of Danshen. P C A H was found to reduce the amount of tau 
phosphorylation by Cdk-5. However, it reduces the amount of p35 expression and the 
amount of total tau expression as shown in the blots using p35 and Tau, respectively 
(Fig. 4.7). 
Apart from PCAH, Salvianolic acid B (SAB) is also an aqueous active component of 
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Danshen. As shown in Fig. 4.7，SAB shows no effect on reducing Cdk-5 induced tau 
phosphorylation. Besides, the expression of transient p35 was slightly reduced after 
SAB treatment (Fig. 4.7). However, SAB showed no effect on reducing tau at HT-7 
sites, but increased the amount of total tau expression. 
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Fig. 4.5 Tau phosphorylation of transfected CHO cells. NT is the control with no 
transfection. For the lanes of +VE control and p35, cells were transfected with 
tauON3R + p35. Different concentrations of roscovitine (lOjaM, 20|j,M and 30|aM) 
were added at 5 hours post-transfection. (A) Endogenous Cdk5 was blotted by Cdk5 
Ab and (B) transient p35 was blotted by p35 Ab. Two replicas were performed. The 
arrows show the relative position of 36kDa, at which Cdk-5 (33kDa) and p35 (35kDa) 
were located. 
97 
NT +VE p35 
r ^ 
\0\xM 20|iM 30|aM 
( \ ( \ ( \ ( \ ( \ 
( A ) - 推 垂 垂 饈 髓 S S : — ^ 
^ M H l i l i ^ l i P ' 9 ^ V ' ^ < r 49kDa 
(B) i i i ^ g a g i ^ g 
l l P I P I P i P f f ^ ^ < 49kDa 
^ W 
Fig. 4.6 Tau phosphorylation of transfected CHO cells. NT is the control with 
no transfection. For the lanes of +VE and p35, Cells were transfected with tauON3R + 
p35. Different concentrations of roscovitine (10}iM, 20|iM and 30\xM) were added at 
5 hours post-transfection. Phosphorylation of tau was blotted by using (A) AT-270, (B) 
HT-7 and (C) Tau antibodies. Two replicas were performed. The arrows show the 
relative position of 49kDa, at which tau (46 to 54kDa) was located. 
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Fig. 4.7 Tau phosphorylation of transfected CHO cells. Cells were transfected with 
tauON3R + p35 and blotted with antibodies for (A) p35 and (B) Cdk-5, (C) AT-270, 
(D) HT-7 and (E) Tau. The cells were treated with SFM and 10|aM roscovitine as a 
positive(+VE) and negative control (lOjiM) respectively. 80|ag of PCAH and SAB 
were added at 5 hours post-transfection. Two replicas were performed. The arrows 
show the relative position of 36kDa and 49kDa, at which Cdk-5 (33kDa), p35 (35kDa) 
and tau (46 to 54kDa) were located. 
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4.4 Discussion 
Apart from GSK-3 (3，Cdk5 is another kinase that induce high phosphorylation of tau 
and cause the formation of NFTs in A D brain. Cdk-5 is a serine/threonine protein 
kinase and association of Cdk-5 with p35, its regulatory subunit, is critical for kinase 
activation. Deregulation of Cdk-5 contributes to the pathogenesis of 
neurodegenerative disease such as AD. In this study, tau phosphorylation by 
Cdk-5/p35 was investigated. Transient p35 activates endogenous Cdk-5 to 
phosphorylate tau in C H O cells. From the result, tau phosphorylation in different 
epitopes in C H O cells by Cdk-5/p35 was characterized by different antibodies. 
Endogenous Cdk-5 but not p35 was found in C H O cells. Consistent to brain specific 
localization of tau, undetectable tau band was found in the no-transfection (NT) lanes 
in HT-7 and Tau blots (Fiq. 4.3). In the absence of p35, even there is a high level of 
Cdk5, the amount of phosphorylated tau is remain unchange. However, after 
cotransfection of p35 and tau, Cdk-5 is activated to hyperphosphorylated tau at the 
sites of Thr 181 and Ser 202 (Fig. 4.4A and B). For the total amount of tau protein, 
activated Cdk-5 highly phosphorylated tau and increased the size of the tau and 
caused the upshift of tau band in the HT-7 and Tau blots. 
Roscovitine is an inhibitor of Cdk-5 and IC50 value for Cdk-5 is 0.16|,LM (Meijer et al” 
1997). At lOjuM roscovitine, nearly all the kinase activity of Cdk-5 was inactivated. 
In Figure 4.5，the effect of roscovitine on Cdk-5 induced tau phosphorylation can be 
evaluated by AT-270, HT-7 and Tau antibodies. It reduces tau phosphorylation at 
epitope Thr 181 and a downshift of band was observed in total tau blots (HT-7 and 
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Tau) (Fig.4.6). TOs indicates that roscovitine reduces phosphorylation of tau and 
converts hyperphosphorylated tau to less phosphorylated state. However, the p35 and 
total tau expression level was reduced when cells were treated with 2 0 _ roscovitine. 
Therefore，10,M roscovitine was used to inhibit CdIc-5 activity and as a negative 
control for the cell model. 
In Fig. 4.7，PCAH exhibited suppression on Cdlc-5 induced tau phosphoo^lation and 
this action is similar with that of roscovitine. However，PCAH reduces the expression 
level ofp35 indicating the effect of P C A H on tau phosphorylation may not be due to 
reduction of kinase activity but due to reduction of the amount of expressed kinase. 
SAB which is another active components of Danshen，but has no effect on reducing 
Cdk-5 induced tau phosphorylation. However，SAB slightly reduced p35 expressed 
level and increased the total tau expression level. 
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Chapter 5 Antioxidant effect of Danshen and its active 
components on lipid peroxidation 
5.1 Introduction 
Extensive evidence exists suggesting that lipid peroxidation is an important 
mechanism of neurodegeneration in A D brain. Indices of lipid peroxidation that are 
altered in A D brain include thiobarbituric acid reactive substances (TEARS), 
phospholipid composition, level of a- and (3-unsaturated aldehydes, activities of 
enzymes that clear lipid peroxidation products, and concentration of isoprostranes 
(Markesbery, 1997). 
In A D brain, free-radical-induced lipid peroxidation is extensive. Ap is widely 
recognized to cause lipid peroxidation in brain cell membranes (Butterfield et al” 
1994; Mark et al., 1999)，leading to the formation of the lipid peroxidation products 
H N E (4-hydroxy-2-trans-nonenal) and acrolein (2-propenal). As these alkenals alter 
the conformation and function of membrane proteins (Lauderback et al,, 2002; 
Pocemich et aL, 2001), they are toxic to neurons (Subramaniam et al., 1997; Mark et 
al., 1997; Lovell et al” 2001), leading to neurodegeneration in A D brain. 
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5.1.1 Red-blood-cell hemolysis model 
It is believed that when cells or tissues are subjected to free-radical-mediated damage 
during oxygen stress, their biomembranes will undergo peroxidation (Miki et al., 
1987). The peroxidation of the erythrocyte membrane resulting in hemolysis has 
therefore been used in my study to investigate intracellular oxygen stress. 
2-2'-azo-bis (2-amidinopropane) dihydrochloride (AAPH) is a water-soluble radical 
chain initiator which can be used to induce hemolysis of red-blood-cell. It induces 
oxidation of lipids (LH) as proceeded as the following reaction (Miki et al, 1987; 
Yamamoto et al., 1984). 
Initiation: (i-e) A-A (i) 
A-N=N-A (AAPH) •【A« IVAj叩 
2eA • (2) 
A« + O, • AOO • (3) 
O2. 
AOO • + LH ~ • AOOH + LOO • (4) 
Propagation: 
LOO • + LH • LOOH + L* (5) 
L* +O2 • LOO • (6) 
Termination: 
2LOO • • Non-radicals (7) 
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A-N=N-A (A = HCl • NHC(NH2)-C(CH3)2-) decomposes to give nitrogen and 
radicals surrounded by a solvent cage when it dissolves in water. Some of these 
radicals recombine to form non-radical products (reaction 1) but some of it escapes 
from the solvent cage to form free radicals (reaction 2). These free radicals rapidly 
react with oxygen to form peroxyl radicals A00» (reaction 3). A 0 0 « either interacts 
with one another to form stable products or attack membrane lipids (LH) to generate 
lipid peroxyl radicals LOO* (reaction 4). Then, LOO* attacks other lipid molecules to 
yeild lipid hydroperoxides (LOOH) and new lipid radicals L» (reaction 5). Under 
anaerobic conditions, these newly formed lipid radicals will interact with oxygen to 
form LOO® (reaction 6) that continuously oxidize other membrane lipids until all of 
them couple with each other to form stable non-radical products (reaction 7). As a 
conclusion, a free radical chain mechanism and even one initiating radical can 
produce large quantities of lipid peroxide through oxidation reaction and eventually 
cause membrane damage. 
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5.2 Materials and methods 
5.2.1 Red-blood-cell hemolysis model 
Red-blood-cell hemolysis model which is mediated by radicals is based on previous 
reports (Miki et al, 1987; Sugiyama et al, 1993). Blood obtained from anesthetized 
male SD rats (300-320g) was collected into heparinized tubes and centrifuged at 1500 
X g for 10 minutes. The supernatant was removed and the pellet was washed three 
times with 0.15 M NaCl. For the first two washes, it was centrifuged at 1500 x g for 
10 minutes, the last wash was centrifuged at 1000 xg for 10 minutes, and this helps to 
remove the plasma and buffy coat from the erythrocytes. Then, a 20% suspension of 
erythrocytes was prepared by adding phosphate -buffered saline (PBS) of pH 7.4. 
Samples at different concentrations and same volume of 400mM A A P H were added 
in succession to two volumes of erythrocyte suspension. The reaction mixture was 
incubated for 3 hours at 37°C with gently shaking. After incubation, an aliquot of the 
reaction mixture was diluted 20 times with PBS and centrifuged at 1000 x g for 10 
minutes. The absorbency (A) of the supernatant at 540nm was read. Similarly, another 
aliquot of the reaction mixture was diluted with distilled water to yield completed 
hemolysis and the absorbance (B) of the supernatant after centrifugation was 
measured at 540 nm. Percentage of inhibition hemolysis exhibited by each sample 




Sprague-Dawley male rats (300-320 g) were supplied from the Laboratory Animal 
Center, The Chinese University of Hong Kong. They were housed under the 
conditions of 22-25 °C and a 12-hour ligt-dark cycle. They were supplied with 
standard animal chow (Picolab Rodent Diet 20，PMI Nutrition International, Inc., 
U.S.A.) ad libitum with free access to tap water. 
5.2.2.2 Chemicals 
Phosphate buffered saline (PBS) 
120mM NaCl, 2.7 m M KCl and 10 m M phosphate buffer at pH 7.4 was purchased 
form Sigma Chemical Company, U.S.A. 
2,2-azo-bis (2-amidinopropane) dihydrochloride (AAPH) 
4 0 0 m M A A P H (Wako, Japan) was prepared in PBS freshly before use. 
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5.3 Result 
5.3.1 Aqueous and ethanol extracts of Danshen 
Although red-blood-cell (RBC) possesses antioxidant defenses itself, it is prone to 
lipid peroxidation under strong oxidative stress. In this study, AAPH, a water-soluble 
radical chain initiator, was used to induce RBC hemolysis and the antioxidant effects 
of Danshen and its active components were evaluted. 
Fig. 5.1 shows the percent inhibition of hemolysis when either aqueous or ethanol 
extracts of Danshen were added. Both of them prevent AAPH-induced hemolysis 
dose dependently when the concentrations between 62.5 p-g/ml to 1000 |Lig/ml were 
applied. At 1000 i^g/ml, aqueous extract and ethanol extract exhibit similarly 
inhibitory effects at about 80%. Ethanol extract and aqueous extract also have similar 
inhibitory effects at low concentration (62.5 |^ g/ml). However, ethanol extract was 
more potent than aqueous extract in inhibiting AAPH-induced hemolysis, at other 
concentration the IC50 value of the ethanol extract was found to be 217.0 |ag/ml, 
which is two times lower than the aqueous extract (406.5 |ig/ml) (Table 5.1). 
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5.3.2 Active components - Protocatechualdehyde and Salvianolic acid B 
The crude extract of Danshen exhibit antioxidant effects on lipid peroxidation, its 
active components may also exhibit certain inhibitory effects on AAPH-induced 
hemolysis. In this study, ascorbic acid, a well known antioxidant, at concentrations 
ranging from 10 j^ g/ml to 160 ^ ig/ml was used as reference to evaluate the potencies 
of Danshen's active components, P C A H and SAB in acting as antioxidants. 
As shown in the Fig. 5.2, P C A H and SAB exhibited higher inhibitory effects than 
ascorbic acid on AAPH-induced hemolysis. At 40 ^iM, ascorbic acid could just 
provide 12.57% inhibition but P C A H could offer 44.47 % prevention and SAB could 
prevent 50.08% inhibition. As reflected by the results shown in Table 5.1, the IC50 
values of P C A H and SAB were found to be 23.3 [jM and 17.3 ^ iM, respectively which 
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Fig. 5.1 Inhibitory effects on AAPH-induced hemolysis by using aqueous and 
ethanol Extracts of Danshen. All data were expressed as mean 土 S E M (n = 3). 
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Fig. 5.2 Inhibitory effects on AAPH-induced hemolysis by using 
protocatechualdehyde, salvianolic acid B and potent antioxidant ascorbic acids. All 
data were expressed as mean 士 S E M (n = 3). 
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Table 5.1 Antioxidant effects of crude extracts and active components of Danshen by 
using hemolysis assay. 
_ 
Aqueous extract of Danshen 406.5 Og/ml) 
Ethanol extract of Danshen 217.0 (|ig/ml) 
Protocatechualdehyde 23.3 (|iM/ml) 
Salvianolic acid B 17.3 (|jM/ml) 
Ascorbic acid 139.3 (jiiM/ml) 
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5.4 Discussion 
Biomembranes such as erythrocytes are rich in polyunsaturated fatty acids which are 
most susceptible to peroxidative damage by free radical attack. Peroxidation of 
biomembranes is found when tissues are damaged during ischemia, inflammation and 
aging (Mead 1976; Donate 1981). In my study, A A P H was used to generate free 
radical to induce hemolysis of erythrocytes and thus the scavenging oxygen free 
radical activity of Danshen was studied. 
Both of the crude extracts and active components (PCAH and SAB) of Danshen have 
been found to exhibit scavenging oxygen free radical activity in present study. When 
comparing with the IC50 of ascorbic acid, both crude extracts showed higher IC50 
values than this potent antioxidant. However, PCAH and SAB have lower IC50 values 
than that of ascorbic acid, they can be considered as powerful antioxidants. 
Danshen crude extracts and its active components may protect RBC membrane from 
free radical attack by either one or combination of following mechanisms. Firstly, 
they may act as a chelator to inactivate Cu^^ and catalytic cations involved in 
initiation of free radicals. Secondly, they may function as a free-radical chain reaction 
interrupter by trapping the free radicals mediated by AAPH. Thirdly, they may 
function synergistically with a-tocopherol by donating hydrogen to regenerate 
a-tocopherol when the latter was oxidized (Salah et al, 1995; Morel et al., 1993). 
When the in vitro relative activity of two crude extracts and two active components 
of Danshen as antioxidants against AAPH-induced hemolysis was compared, PCAH 
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and SAB were more effective against AAPH-induced hemolysis than the crude 
extracts. When comparing the effect of P C A H and SAB, SAB exhibit more powerful 
inhibitory effect than PCAH. The varying effect of PCAH and SAB on 
AAPH-induced membrane oxidation was probably related to the number and position 
of their hydroxyl groups. There are three phenol hydroxyl groups in SAB and only 
one in P C A H (Fig. 5.3)， so SAB is a better hydrogen donor and more hydrophilic, 
therefore more chelating power to catalytic cations such as Cu 2+. 
The fact that age is a risk factor in A D has provided initial support to the hypothesis 
that oxygen radicals, like in the aging process, could be involved. Although A D is 
likely to be associated with multiple etiologies and mechanisms, it is evident that 
oxidative stress is part of it. There are accumulating evidence that oxidative stress is a 
feature of A D (Pratico and Delanty, 2000). Lipid peroxidation is a major consequence 
of intracellular free radical involves in neuronal death (Smith and Perry, 1995) 
because of its high lipid content and unusually high concentration of polyunsaturated 
fatty acids that are particularly susceptible to oxidation. There is experimental 
evidence that the neurotoxicity of p-amyloid is mediated via free radicals, and 
oxidative stress increases accumulation of p-amyloid (Gibson et al., 2000). Moreover, 
evidence in both in vitro and animal studies suggest that treatment with antioxidant 
agents may be useful in neurologic disorder, including A D (Pratico and Delanty, 
2000). M y results demonstrated that PCAH and SAB have a strong protective action 
against oxygen free radical induced peroxidative damage to biomembrane, they may 
be used as powerful antioxidants which may reduce free radical damage in neuronal 
cell in A D patient. 
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Chapter 6 General discussion and Outlook 
6.1 General discussion 
In this study, I have carried out three areas of work: Firstly, I have tested the effect of 
aqueous and ethanol extracts of Danshen, PCAH and SAB on the tau phosphorylation 
in GSK-3p/tauON3R co-transfected Cos-7 cells. Secondly, the tau phosphorylation by 
Cdk5/p35 was studied by p35/tauON3R co-transfected C H O cells. The effects of 
roscovitine, P C A H and SAB on Cdk-5 induced phosphorylation of tau were studied. 
In these two parts of work，different anti-tau antibodies (AT-270, AT-180, AT-8, 
PHF-1, HT-7 and Tau) were used to assay the change in phosphorylation pattern of 
tau. Finally, I have analyzed the free radical scavenging ability of aqueous and ethanol 
extract of Danshen, PCAH and SAB by using AAPH-induced RBC hemolysis model. 
In Chapter 3，I have found that aqueous extract of Danshen can effectively reduce 
GSK-3P induced tau phosphorylation. The two aqueous active components of 
Danshen, P C A H and SAB also showed inhibitory effect on tau phosphorylation. 
However, although PCAH reduced tau phosphorylation in the sites Thr231, ThrlSl, 
Ser 202, Ser 396 and Ser 404，it also reduced the expression level of transient 
GSK-3P and total tau protein in Cos-7 cells. Apart from that, PCAH showed 
inhibitory effect on Cdk-5/p35 induced tau phosphorylation in C H O cells and reduced 
transient p35 and total tau protein expression level. These indicated that the effect of 
P C A H on tau phosphorylation may not be due to reduction of kinase activity but due 
to reduction of the amount of expressed kinase. 
SAB can reduce GSK-3P induced phosphorylation of tau at the epitopes of Thr231, 
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ThrlSl, Ser 202, Ser 396 and Ser 404 in dose dependent manner. Besides, it will not 
affect the expression of GSK-3 p in Cos-7 cells, thus its inhibitory effect on tau 
phosphorylation may due to GSK-3 p activity reduction or other phosphatases 
activation. However, SAB has no effect on Cdk-5 induced tau phosphorylation which 
means that its action is only specific for GSK-3 P induced tau phosphorylation. 
Apart from that, SAB was most promising in preventing AAPH-induced RBC 
hemolysis and its IC50 value was estimated to be 17.3 |xM. SAB was more effective 
than P C A H (IC50 = 23.3) and significantly more effective than ascorbic acid (IC50 = 
139.3 loM) which is a well-known antioxidant. 
As a preliminary result, SAB can reduce GSK-3 p induce tau phosphorylation and 
exhibit strong antioxidant activity in protecting damage of biomembrane. It may have 
pharmacological effect on A D by downregulating GSK-3 p activity on tau and may 
reduce free radical damage in neuronal cells. 
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6.2 Proposed study in the future 
6.2.1 In vitro kinase assay using gamma^^P ATP and substrate with or 
without TCM 
In the first part of this study, SAB have shown that it can reduce GSK-3 p induced 
phosphorylation of tau at the epitopes of Thr231, ThrlSl, Ser 202, Ser 396 and Ser 
404 in dose dependent manner. By using cell model, there may involve other parties 
on affecting the inhibitory effect of SAB. In order to eliminate these factors, in vitro 
kinase assay can be used to study the effect of SAB on GSK-3 p activity. 
6.2.2 Use of neuroblastoma cells (SHSY-5Y) to study the effect of Danshen 
and its active components on tau phosphorylation 
In order to know the actual effect of T C M on tau phosphorylation in neuronal cells, 
neuroblastoma cells can be used instead of Cos-7 or C H O cells. In A D brain, 
endogenous tau can be affected by many factors like Ap，GSK-3(3, Cdk-5 and free 
radical. By treating the neuroblastoma cells with different TCM, the effect of T C M 
can be evaluated by studying the amount of hyperphosphorylated tau, the secretion of 
Ap from APP and the amount ofMDA. 
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6.2.3 Thiobarbituric acid-reacting substances (TBARS) assay 
Lipid peroxidation is the most studied indexes of oxidatant stress in AD. Although 
R B C hemolysis model has been extensively studied as a model for lipid peroxidative 
damage, the model is based on biomembrane damage rather than neuronal damage. 
Malondialdehyde (MDA) is the best known lysine-dependent crosslinking agent 
generated by lipid peroxidation (Pratico and Delanty, 2000). By measuring M D A 
level in TBARS assays, brain membrane lipid peroxidation can be quantitatively 
assessed. This may confirm the antioxidant effect of SAB can reducing the oxidative 
stress in brain. 
6.2.4 In vitro phosphatase kinase assay 
The abnormal hyperphosphorylation also promotes the self assembly of tau into 
tangles of PHF. The hyperphosphorylation of tau in A D is probably due to a protein 
phosphorylation/dephosphorylation imbalance produced by a decrease in the activity 
of protein phosphatase (PP)-2A (Iqbal et al., 2002) and increase in the activities of tau 
kinases (GSK-3 P). Therefore, the effect of Danshen on phosphatase can be studied by 
using cell model or in vitro phosphatase assay. 
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